洛丁新和尼群地平对高血压病患者血浆纤维蛋白原和血小板聚集的影响

Effects of lotensin and nitrendipine on plasma fibrinogen andplatelet aggregation in hypertensive patients

为探讨洛丁新和尼群地平对高血压病患者血浆纤维蛋白原和血小板聚集的影响，采用免疫比浊法、比浊法测定高血压病患者及正常人血浆纤维蛋白原和血小板聚集。４７例高血压患者中，２４例用洛丁新治疗，２３例用尼群地平治疗。结果显示：治疗前高血压病患者血浆纤维蛋白原升高，血小板聚集增强。用二药分别治疗８周后，高血压患者血小板聚集下降，洛丁新降低血浆纤维蛋白原，而尼群地平对纤维蛋白原则无影响。

Plasma fibrinogen and platelet aggregation were measured by turbidimetric immunoassay, turbidimetry in 47 hypertensive patients and 20 normotensive control subjects. Among the 47 hypertensives, 24 cases were received lotensin and 23 nitrendipine. The plasma fibrinogen was increased and platelet aggregation enhanced in hypertensive patients before treatment. Platelet aggregation decreased after 8 weeks of treatment with lotensin or nitrendipine respectively. Lotensin decreased plasma fibrinogen whereas nitrendipine did not. It was concluded that both lotensin and nitrendipine decreased platelet aggregation; lotensin decreased plasma fibrinogen but nitrendipine did not.